Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Amsterdam  >  Kiadis Pharma N.V.    KDS   NL0011323407

KIADIS PHARMA N.V.

(KDS)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Amsterdam
07/07/2020 07/08/2020 07/09/2020 07/10/2020 07/13/2020 Date
1.403(c) 2.15(c) 2.022(c) 2(c) 1.97 Last
130 147 8 077 759 1 972 898 1 251 902 333 832 Volume
+0.21% +53.24% -5.95% -1.09% -1.50% Change
More quotes
Financials
Sales 2020 3,08 M 3,48 M 3,48 M
Net income 2020 -31,8 M -36,0 M -36,0 M
Net Debt 2020 - - -
P/E ratio 2020 -2,27x
Yield 2020 -
Sales 2021 1,33 M 1,50 M 1,50 M
Net income 2021 -37,1 M -41,9 M -41,9 M
Net Debt 2021 - - -
P/E ratio 2021 -2,15x
Yield 2021 -
Capitalization 80,1 M 90,6 M 90,6 M
Capi. / Sales 2020 26,0x
Capi. / Sales 2021 60,4x
Nbr of Employees 170
Free-Float 96,6%
More Financials
Company
Kiadis Pharma N.V., is a fully integrated biopharmaceutical company committed to developing innovative therapies for patients with life-threatening diseases. With headquarters in Amsterdam, the Netherlands, and offices in the US and across Europe, Kiadis Pharma N.V. is leveraging the natural strengths of humanity and our collective immune system to source the best cells for life. 
More about the company
Latest news on KIADIS PHARMA N.V.
06/25KIADIS PHARMA N : Announces Results of Annual General Meeting of Shareholders
AQ
06/19KIADIS PHARMA N : to present at the Virtual European Biotech Investor Day 2020
AQ
05/13KIADIS PHARMA N : Notice of Annual General Meeting of Shareholders
AQ
04/30KIADIS PHARMA N : announces annual results for the year ended December 31, 2019 ..
AQ
04/30KIADIS PHARMA N : announces €5 million private placement with Life Sciences Part..
AQ
04/30KIADIS PHARMA N.V. : Admission of new securities
CO
04/30KIADIS PHARMA N.V. : Annual results
CO
04/28KIADIS PHARMA N : to announce annual results for the year ended December 31, 201..
AQ
04/28KIADIS PHARMA N : announces €12 million private placement with a U.S. healthcare..
AQ
04/09KIADIS PHARMA N : files first investigational new drug application with the U.S...
AQ
03/31KIADIS PHARMA N.V. : Crossing thresholds
CO
2019KIADIS PHARMA N.V. : Annual Report
CO
2019KIADIS PHARMA N.V. : Corporate Officers and Executives' transactions in the comp..
CO
2019KIADIS PHARMA N : changes strategy to focus solely on development of Natural Kil..
AQ
2019KIADIS PHARMA N : to present at the American Society of Hematology 2019 Annual M..
AQ
More news
News in other languages on KIADIS PHARMA N.V.
06/25KIADIS PHARMA N : Announces Results of Annual General Meeting of Shareholders
06/19KIADIS PHARMA N : to present at the Virtual European Biotech Investor Day 2020
05/13KIADIS PHARMA N : Notice of Annual General Meeting of Shareholders
04/30KIADIS PHARMA N : announces annual results for the year ended December 31, 2019 ..
04/30KIADIS PHARMA N : announces €5 million private placement with Life Sciences Part..
More news
Chart KIADIS PHARMA N.V.
Duration : Period :
Kiadis Pharma N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KIADIS PHARMA N.V.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 3,35 €
Last Close Price 2,00 €
Spread / Highest target 125%
Spread / Average Target 67,5%
Spread / Lowest Target 20,0%
EPS Revisions
Managers
NameTitle
Arthur K. Lahr Chief Executive Officer
Mark A. Wegter Chairman-Supervisory Board
Dirk de Naeyer Chief Operating Officer
Andrew S. Sandler Chief Medical Officer
Robert Friesen Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
KIADIS PHARMA N.V.0.50%91
LONZA GROUP52.43%42 546
CELLTRION, INC.79.28%36 149
SEATTLE GENETICS, INC.52.59%30 180
IQVIA HOLDINGS INC.-7.66%27 247
MODERNA, INC.220.09%24 344